Patents by Inventor Kengo Sumi
Kengo Sumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11918372Abstract: A cognitive function evaluation device includes: an obtainment unit that obtains utterance data indicating a voice of an evaluatee uttering a sentence as instructed; a calculation unit that calculates, from the utterance data obtained by the obtainment unit, a feature based on the utterance data; an evaluation unit that compares the feature calculated by the calculation unit to reference data indicating a relationship between voice data indicating a voice of a person and a cognitive function of the person to evaluate the cognitive function of the evaluatee; and an output unit that outputs the sentence to be uttered by the evaluatee and outputs a result of evaluation by the evaluation unit.Type: GrantFiled: October 15, 2018Date of Patent: March 5, 2024Assignee: Panasonic Intellectual Property Management Co., Ltd.Inventors: Sadayuki Sumi, Ryosuke Nagumo, Kengo Abe, Yoshihiro Matsumura, Takashi Nishiyama, Hirobumi Nakajima, Kohji Sasabe, Makoto Kariyasu, Takako Yoshimura, Minoru Toyama
-
Patent number: 11535595Abstract: A compound, such as isoquinoline-6-sulfonyl chloride acid and/or addition salts thereof, may be useful as a manufacturing intermediate for an isoquinoline-6-sulfonamide compound. A method for manufacturing such compounds and/or or acid addition salts thereof, may involve subjecting 6-(benzylthio)isoquinoline to an oxidative chlorination reaction and/or reacting 6-aminoisoquinoline with a nitrite or nitrous acid ester, then with thionyl chloride, and then with an acid.Type: GrantFiled: December 16, 2019Date of Patent: December 27, 2022Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Kengo Sumi, Ryohei Nakamura
-
Patent number: 11427546Abstract: A stable crystal of a salt of N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide may have desirable properties for a pharmaceutical drug substance, and more specifically N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide dihydrochloride anhydride. A crystal of the anhydride may have characteristic peaks at 2? angles of 6.8±0.1°, 10.0±0.1°, 12.7±0.1°, 14.6±0.1°, 14.8±0.1°, 16.2±0.1°, 17.4±0.1°, 17.8±0.1°, 19.5±0.1°, 20.0±0.1°, 21.6±0.1°, 24.7±0.1°, 25.5±0.1°, 25.8±0.1°, 29.8±0.1°, 39.5±0.1°, and/or 44.9±0.1° in powder X-ray diffraction spectrum.Type: GrantFiled: December 16, 2019Date of Patent: August 30, 2022Assignee: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Hiroyoshi Hidaka, Kengo Sumi, Takashi Izuhara
-
Publication number: 20220017469Abstract: A stable crystal of a salt of N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide may have desirable properties for a pharmaceutical drug substance, and more specifically N—[(R)-1-{(S)-2-hydroxy-2-phenylpropylamino}propan-2-yl]isoquinoline-6-sulfonamide dihydrochloride anhydride. A crystal of the anhydride may have characteristic peaks at 2? angles of 6.8±0.1°, 10.0±0.10, 12.7±0.10, 14.6±0.1°, 14.8±0.1°, 16.2±0.1°, 17.4±0.1°, 17.8±0.1°, 19.5±0.1°, 20.0±0.1°, 21.6±0.1°, 24.7±0.10, 25.5±0.1°, 25.8±0.1°, 29.8-0.1°, 39.5-0.1°, and/or 44.9±0.1° in powder X-ray diffraction spectrum.Type: ApplicationFiled: December 16, 2019Publication date: January 20, 2022Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Hiroyoshi HIDAKA, Kengo SUMI, Takashi IZUHARA
-
Publication number: 20210395205Abstract: A compound, such as isoquinoline-6-sulfonyl chloride acid and/or addition salts thereof, may be useful as a manufacturing intermediate for an isoquinoline-6-sulfonamide compound. A method for manufacturing such compounds and/or or acid addition salts thereof, may involve subjecting 6-(benzylthio)isoquinoline to an oxidative chlorination reaction and/or reacting 6-aminoisoquinoline with a nitrite or nitrous acid ester, then with thionyl chloride, and then with an acid.Type: ApplicationFiled: December 16, 2019Publication date: December 23, 2021Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Kengo SUMI, Ryohei NAKAMURA
-
Publication number: 20210371396Abstract: A method may produce an isoquinoline-6-sulfonamide derivative useful as a medicinal drug; and an intermediate which is used for the method, and more specifically, a 1,4-diazocane compound of formula (8), wherein R4 is an amino protecting group, or a salt thereof.Type: ApplicationFiled: November 1, 2019Publication date: December 2, 2021Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INC.Inventors: Kengo SUMI, Tomoyuki KOIDE, Osamu KIMATA, Yuji TAKASHIMA, Kazunao MASUBUCHI
-
Patent number: 8951997Abstract: The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH?CH, O, or S; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, an alkyl group, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like, or R3 and R4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and l, m, and n represent an integer number of 1 to 4.Type: GrantFiled: June 18, 2010Date of Patent: February 10, 2015Assignee: D. Western Therapeutics Institute, Inc.Inventors: Hiroyoshi Hidaka, Kouichi Takahashi, Yoshihiro Inoue, Kengo Sumi, Ryohei Nakamura
-
Patent number: 8883792Abstract: The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein R1 and R2 each independently represent a hydrogen atom, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like; R5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and A represents a linear or branched alkylene group having 2 to 6 carbon atoms.Type: GrantFiled: December 21, 2011Date of Patent: November 11, 2014Assignee: D. Western Therapeutics Institute, Inc.Inventors: Hiroyoshi Hidaka, Kengo Sumi, Kouichi Takahashi, Yoshihiro Inoue
-
Publication number: 20130274269Abstract: The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein R1 and R2 each independently represent a hydrogen atom, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like; R5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and A represents a linear or branched alkylene group having 2 to 6 carbon atoms.Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Applicant: D. Western Therapeutics Institute, Inc.Inventors: Hiroyoshi Hidaka, Kengo Sumi, Kouichi Takahashi, Yoshihiro Inoue
-
Publication number: 20120035159Abstract: The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt: wherein X and Y each independently represent a direct bond, NH, CH?CH, O, or S; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, an alkyl group, or the like; R3 and R4 each independently represent a hydrogen atom, an alkyl group, or the like, or R3 and R4 together form an alkylene group or an alkenylene group, which may be bridged between two carbon atoms to an arbitrary position; and l, m, and n represent an integer number of 1 to 4.Type: ApplicationFiled: June 18, 2010Publication date: February 9, 2012Applicant: D. WESTERN THERAPEUTICS INSTITUTE, INCInventors: Hiroyoshi Hidaka, Kouichi Takahashi, Yoshihiro Inoue, Kengo Sumi, Ryohei Nakamura
-
Publication number: 20080064681Abstract: The present invention provides compounds useful as therapeutic agent for treating glaucoma and methods for treating glaucoma. That is, a therapeutic agent for treating glaucoma containing, as an active ingredient, a compound represented by formula (1) below is synthesized, and the therapeutic agent is administered in the form of eye drops to a glaucoma patient. Thus, the intraocular pressure is reduced. In the above formula, ring A represents a 5- to 11-membered cyclic amino group, which may have a substituted group, and X represents a halogen.Type: ApplicationFiled: September 11, 2006Publication date: March 13, 2008Inventors: Hiroyoshi Hidaka, Masahiro Nishio, Kengo Sumi